A Phase III Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Multiple-Dose Clinical Trial to Study the Efficacy and Safety of MK0663/Etoricoxib 90 and 120 mg, Ibuprofen 600 mg, and Acetaminophen 600 mg/Codeine 60 mg in the Treatment of Patients With Postoperative Dental Pain.

Trial Profile

A Phase III Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Multiple-Dose Clinical Trial to Study the Efficacy and Safety of MK0663/Etoricoxib 90 and 120 mg, Ibuprofen 600 mg, and Acetaminophen 600 mg/Codeine 60 mg in the Treatment of Patients With Postoperative Dental Pain.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2013

At a glance

  • Drugs Etoricoxib (Primary) ; Ibuprofen; Paracetamol/codeine
  • Indications Dental pain; Postoperative pain
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 02 Sep 2010 Primary endpoint results presented at the 13th World Congress on Pain
    • 23 Oct 2009 Actual patient number (460) added as reported by ClinicalTrials.gov.
    • 04 Sep 2009 Planned number of patients changed from 460 to 588 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top